Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TCMD 
Tactile Systems Technology Inc (TCMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TCMD (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 106.71% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 312.86M USD | Price to earnings Ratio 18.89 | 1Y Target Price 21.5 |
Price to earnings Ratio 18.89 | 1Y Target Price 21.5 | ||
Volume (30-day avg) 296628 | Beta 1.24 | 52 Weeks Range 11.12 - 21.10 | Updated Date 04/1/2025 |
52 Weeks Range 11.12 - 21.10 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.79% | Operating Margin (TTM) 14.62% |
Management Effectiveness
Return on Assets (TTM) 4.79% | Return on Equity (TTM) 8.27% |
Valuation
Trailing PE 18.89 | Forward PE 23.64 | Enterprise Value 249539165 | Price to Sales(TTM) 1.07 |
Enterprise Value 249539165 | Price to Sales(TTM) 1.07 | ||
Enterprise Value to Revenue 0.85 | Enterprise Value to EBITDA 7.71 | Shares Outstanding 23665800 | Shares Floating 21429018 |
Shares Outstanding 23665800 | Shares Floating 21429018 | ||
Percent Insiders 2.59 | Percent Institutions 97.12 |
Analyst Ratings
Rating 4 | Target Price 24 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tactile Systems Technology Inc
Company Overview
History and Background
Tactile Systems Technology, Inc. was founded in 1993. It is a medical technology company focused on developing and marketing innovative medical devices for the treatment of chronic diseases.
Core Business Areas
- Lymphedema Therapy: Develops and markets pneumatic compression devices for lymphedema and chronic venous insufficiency treatment. This includes their Flexitouch and Entre systems.
Leadership and Structure
Raymond F. Huml is the CEO. The company has a standard corporate structure with departments for sales, marketing, R&D, and operations.
Top Products and Market Share
Key Offerings
- Flexitouch Plus System: An advanced pneumatic compression device used for lymphedema treatment. Competitors include LymphaPress and Bio Compression Systems.
- Entre System: A pneumatic compression device used for chronic venous insufficiency. Competitors include Lympha Press and Bio Compression Systems.
Market Dynamics
Industry Overview
The market focuses on pneumatic compression therapy for chronic conditions. The industry includes several competitors that develop and market pneumatic compression devices.
Positioning
Tactile Systems Technology Inc. holds a significant position in the pneumatic compression therapy market. Their competitive advantage comes from the advanced features of their Flexitouch system
Total Addressable Market (TAM)
The TAM for lymphedema and venous insufficiency treatment is estimated to be several billion dollars globally. Tactile is well-positioned to capture a portion of this market due to its proprietary technologies
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Established market presence
- Innovative technology
- Focus on chronic diseases
- Experienced management team
Weaknesses
- Reliance on reimbursement policies
- Limited product diversification
- Dependence on a single sales channel
Opportunities
- Expanding into new geographic markets
- Developing new products and applications
- Acquiring complementary businesses
- Increasing awareness of lymphedema and venous insufficiency
Threats
- Increased competition
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- BSGM
- TACT
Competitive Landscape
Tactile Systems Technology has a competitive edge due to its advanced technology and focus on patient outcomes. However, it faces competition from larger players with more resources and established relationships with healthcare providers.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Tactile Systems Technology has experienced moderate growth in recent years, driven by increased adoption of their Flexitouch system and expansion into new markets.
Future Projections: Analysts predict continued growth for Tactile Systems Technology, driven by increased awareness of lymphedema and venous insufficiency, aging population, and advancements in pneumatic compression therapy.
Recent Initiatives: Focus on direct-to-patient marketing, expanding sales team, and investing in R&D for new product development.
Summary
Tactile Systems Technology, Inc. is a stable company in the chronic disease treatment market. Its strengths lie in its innovative technology and market presence. However, it needs to manage reimbursement policies and competition. Growth opportunities include expansion into new markets.
Similar Companies
- BSGM
- TACT
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tactile Systems Technology Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2016-07-28 | CEO, President & Director Ms. Sheri Louise Dodd | ||
Sector Healthcare | Industry Medical Devices | Full time employees 1037 | Website https://tactilemedical.com |
Full time employees 1037 | Website https://tactilemedical.com | ||
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.